ECSP14013206A - Hemifumarato de tenofovir alafenamida - Google Patents

Hemifumarato de tenofovir alafenamida

Info

Publication number
ECSP14013206A
ECSP14013206A ECSP14013206A ECSP14013206A EC SP14013206 A ECSP14013206 A EC SP14013206A EC SP14013206 A ECSP14013206 A EC SP14013206A EC SP14013206 A ECSP14013206 A EC SP14013206A
Authority
EC
Ecuador
Prior art keywords
tenofovir alafenamide
alafenamide hemifumarate
hemifumarate
phenoxyphosphinyl
isopropoxycarbonyl
Prior art date
Application number
Other languages
English (en)
Inventor
Richard Yu
Dazhan Liu
Bing Shi
Fang Wang
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46785793&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14013206(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of ECSP14013206A publication Critical patent/ECSP14013206A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una forma de hemifumarato de 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxicarbonil)etil]-amino]fenoxifosfinil]metoxi]propil]adenina (tenofovir alafenamida) y la terapia antiviral que utiliza hemifumarato de tenofovir alafenamida (p.ej., las terapias anti-HIV y anti-HBV).
ECSP14013206 2011-08-16 2014-02-13 Hemifumarato de tenofovir alafenamida ECSP14013206A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161524224P 2011-08-16 2011-08-16

Publications (1)

Publication Number Publication Date
ECSP14013206A true ECSP14013206A (es) 2014-03-31

Family

ID=46785793

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP14013206 ECSP14013206A (es) 2011-08-16 2014-02-13 Hemifumarato de tenofovir alafenamida

Country Status (41)

Country Link
US (2) US8754065B2 (es)
EP (3) EP3831832A1 (es)
JP (5) JP5651275B2 (es)
KR (1) KR101612642B1 (es)
CN (2) CN103732594A (es)
AP (1) AP3639A (es)
AR (1) AR087546A1 (es)
AU (1) AU2012296622C1 (es)
BR (1) BR112014003420B1 (es)
CA (1) CA2845553C (es)
CL (1) CL2014000370A1 (es)
CO (1) CO6880063A2 (es)
CR (1) CR20140072A (es)
CY (1) CY1118385T1 (es)
DK (1) DK2744810T4 (es)
EA (1) EA027768B1 (es)
EC (1) ECSP14013206A (es)
ES (1) ES2608871T5 (es)
FI (1) FI2744810T4 (es)
HK (1) HK1199026A1 (es)
HR (1) HRP20161696T4 (es)
HU (1) HUE031253T2 (es)
IL (2) IL230949A (es)
IN (1) IN2014DN01012A (es)
LT (1) LT2744810T (es)
MA (1) MA35350B1 (es)
MD (1) MD4508C1 (es)
ME (1) ME02612B (es)
MX (1) MX336627B (es)
PE (1) PE20141328A1 (es)
PL (1) PL2744810T5 (es)
PT (1) PT2744810T (es)
RS (1) RS55353B2 (es)
SG (1) SG2014011548A (es)
SI (1) SI2744810T2 (es)
SM (1) SMT201600476B (es)
TW (1) TWI516499B (es)
UA (1) UA115311C2 (es)
UY (1) UY34262A (es)
WO (1) WO2013025788A1 (es)
ZA (1) ZA201400582B (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI2744810T4 (fi) 2011-08-16 2023-11-22 Gilead Sciences Inc Tenofoviirialafenamidihemifumaraatti
WO2013052094A2 (en) 2011-10-07 2013-04-11 Gilead Sciences, Inc. Methods for preparing anti-viral nucleotide analogs
EP2809323A1 (en) * 2012-02-03 2014-12-10 Gilead Sciences, Inc. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
WO2015040640A2 (en) * 2013-09-20 2015-03-26 Laurus Labs Private Limited An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof
TWI660965B (zh) * 2014-01-15 2019-06-01 美商基利科學股份有限公司 泰諾福韋之固體形式
US9463194B2 (en) 2014-02-05 2016-10-11 Gilead Sciences, Inc. Methods of treating patients co-infected with HIV and tuberculosis
CN105085571A (zh) * 2014-05-20 2015-11-25 四川海思科制药有限公司 替诺福韦艾拉酚胺复合物及其制备方法和用途
CN108191913A (zh) * 2014-11-12 2018-06-22 四川海思科制药有限公司 一种替诺福韦艾拉酚胺晶型a及其制备方法
CN105237571B (zh) * 2014-11-28 2018-03-09 成都苑东生物制药股份有限公司 9‑[(r)‑2‑[[(s)‑[[(s)‑1‑(异丙氧基羰基)乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤的盐
CN104558036A (zh) * 2014-12-11 2015-04-29 杭州和泽医药科技有限公司 一种替诺福韦艾拉酚胺半反丁烯二酸盐晶型及其制备方法
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
BR112017014085A2 (pt) * 2015-01-03 2018-01-09 Mylan Laboratories Ltd processos para a preparação de hemifumarato de tenofovir alafenamida amorfo e uma pré-mistura do mesmo
CN105669751B (zh) * 2015-03-05 2018-09-21 洛阳聚慧医药科技有限公司 非环核苷酸磷酰胺类化合物及其盐的制备以及在抗病毒方面的应用
GB201509431D0 (en) * 2015-06-01 2015-07-15 Equigerminal Sa Antiviral composition
CZ2015384A3 (cs) 2015-06-05 2016-12-14 Zentiva, K.S. Pevné formy Tenofovir alafenamidu
JP2018524308A (ja) * 2015-06-17 2018-08-30 ギリアード サイエンシーズ， インコーポレイテッド テノホビルアラフェナミドの共結晶、塩および結晶形態
KR102121329B1 (ko) 2015-06-30 2020-06-17 길리애드 사이언시즈, 인코포레이티드 테노포비르 및 엠트리시타빈을 포함하는 제약 제제
WO2017007701A1 (en) * 2015-07-07 2017-01-12 Merck Sharp & Dohme Corp. Antiviral phosphodiamide compounds
US9822138B2 (en) 2015-08-10 2017-11-21 Merck Sharp & Dohme Corp. Antiviral beta-amino acid ester phosphodiamide compounds
WO2017037608A1 (en) * 2015-08-28 2017-03-09 Laurus Labs Private Limited Solid forms of tenofovir alafenamide and salts thereof, processes for its preparation and pharmaceutical compositions thereof
CN108348473B (zh) 2015-11-09 2021-06-18 吉利德科学公司 治疗人免疫缺陷病毒的治疗组合物
CN106699812A (zh) * 2015-11-12 2017-05-24 江苏豪森药业集团有限公司 替诺福韦前药的制备和纯化方法
EP3386512B1 (en) 2015-12-10 2023-11-22 Merck Sharp & Dohme LLC Antiviral phosphodiamide prodrugs of tenofovir
US10450335B2 (en) 2015-12-15 2019-10-22 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
PT3411378T (pt) 2016-02-02 2020-07-28 Sandoz Ag Formas cristalinas de monofumarato de tenofovir alafenamida
CN107226826A (zh) * 2016-03-25 2017-10-03 江苏奥赛康药业股份有限公司 替诺福韦艾拉酚胺富马酸盐化合物及其药物组合物
WO2017203395A1 (en) * 2016-05-21 2017-11-30 Shilpa Medicare Limited Crystalline forms of tenofovir alafenamide hemi fumarate
WO2017211325A1 (zh) * 2016-06-05 2017-12-14 上海诚妙医药科技有限公司 富马酸替诺福韦艾拉酚胺盐的新晶型、制备方法及其用途
MA50673A (fr) 2016-08-19 2020-08-05 Gilead Sciences Inc Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus vih
WO2018039157A1 (en) 2016-08-25 2018-03-01 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
CN107793451A (zh) * 2016-08-30 2018-03-13 江苏奥赛康药业股份有限公司 替诺福韦艾拉酚胺半富马酸盐化合物及其药物组合物
WO2018044822A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinations and uses and treatments thereof
WO2018051250A1 (en) 2016-09-14 2018-03-22 Viiv Healthcare Company Combination comprising tenofovir alafenamide, bictegravir and 3tc
WO2018080903A1 (en) 2016-10-26 2018-05-03 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
CN108117570A (zh) * 2016-11-28 2018-06-05 正大天晴药业集团股份有限公司 一种替诺福韦艾拉酚胺半富马酸盐的结晶及其制备方法
CN108129514A (zh) * 2016-12-01 2018-06-08 北京美倍他药物研究有限公司 磷酸/膦酸衍生物的单一异构体及其医药用途
CN108070003A (zh) * 2016-12-02 2018-05-25 上海博志研新药物技术有限公司 替诺福韦艾拉酚胺半反丁烯二酸盐晶型及制备方法和应用
BR112019013017A2 (pt) 2016-12-22 2020-01-14 Idenix Pharmaceuticals Llc compostos de éster alifático antiviral de tenofovir ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e uso dos mesmos
RU2019122625A (ru) * 2016-12-22 2021-01-22 Мерк Шарп И Доум Корп. Противовирусные бензиламин-фосфодиамидные соединения
WO2018113652A1 (zh) 2016-12-23 2018-06-28 四川科伦博泰生物医药股份有限公司 核苷磷酸类化合物及其制备方法和用途
WO2018115046A1 (en) 2016-12-23 2018-06-28 Sandoz Ag Crystalline solid forms of tenofovir alafenamide
TW202402300A (zh) 2017-01-31 2024-01-16 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
WO2018153977A1 (en) 2017-02-24 2018-08-30 Hexal Ag Stable composition of tenofovir alafenamide
RU2659388C1 (ru) 2017-02-28 2018-07-02 Васильевич Иващенко Александр Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
CN108794530A (zh) * 2017-04-26 2018-11-13 上海医药工业研究院 一种替诺福韦丙酚酰胺盐晶型及其制备方法和用途
CN107445994A (zh) * 2017-05-31 2017-12-08 北京阜康仁生物制药科技有限公司 替诺福韦艾拉酚胺半富马酸盐新晶型
RU2662160C9 (ru) 2017-07-03 2018-10-22 Александрович Иващенко Андрей Комбинированный лекарственный препарат для терапии вирусных инфекций
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
CN107522743A (zh) * 2017-09-30 2017-12-29 深圳科兴生物工程有限公司 一种半富马酸替诺福韦艾拉酚胺工业化连续生产方法
CN107865874A (zh) * 2017-10-23 2018-04-03 上海博悦生物科技有限公司 一种替诺福韦艾拉酚胺的药物组合物及其制备方法
WO2019084020A1 (en) 2017-10-24 2019-05-02 Gilead Sciences, Inc. METHODS OF TREATING PATIENTS CO-INFECTED BY A VIRUS AND TUBERCULOSIS
CA3082191C (en) 2017-12-07 2021-09-21 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US20200407382A1 (en) 2017-12-30 2020-12-31 Cipla Limited Polymorphic forms of (9-[(r)-2-[[(s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]phenoxy phosphinyl]methoxy]propyl] adenine and pharmaceutically acceptable salts thereof
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
CN116854630A (zh) 2018-02-16 2023-10-10 吉利德科学公司 用于制备可用于治疗逆转录病毒科病毒感染的治疗性化合物的方法和中间体
CN108440596B (zh) * 2018-03-22 2020-07-03 科兴生物制药股份有限公司 一种半富马酸替诺福韦艾拉酚胺的新型制备工艺
WO2019237957A1 (zh) 2018-06-12 2019-12-19 四川科伦博泰生物医药股份有限公司 膦酰胺酯化合物及其盐和相关晶体形式、制备方法和用途
JP2021530523A (ja) 2018-07-16 2021-11-11 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のためのカプシド阻害剤
US11826375B2 (en) 2018-07-19 2023-11-28 Merck Sharp & Dohme Llc Phosphinic amide prodrugs of tenofovir
CN112996517A (zh) 2018-09-19 2021-06-18 吉利德科学公司 预防hiv的整合酶抑制剂
KR102054104B1 (ko) * 2019-04-30 2019-12-09 유니셀랩 주식회사 신규한 테노포비어 알라펜아미드 염 및 이의 제조방법
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
CN110452268A (zh) * 2019-08-21 2019-11-15 天地恒一制药股份有限公司 一种丙酚替诺福韦半富马酸单晶的制备方法
EP4065116A1 (en) 2019-11-26 2022-10-05 Gilead Sciences, Inc. Capsid inhibitors for the prevention of hiv
EP4085062A1 (en) 2020-02-20 2022-11-09 Cipla Limited Novel salts and/or co-crystals of tenofovir alafenamide
CN115605493A (zh) 2020-03-20 2023-01-13 吉利德科学公司（Us） 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法
KR20210125298A (ko) 2020-04-08 2021-10-18 주식회사 파마코스텍 테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법
US11680064B2 (en) 2020-06-25 2023-06-20 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
WO2022103758A1 (en) 2020-11-11 2022-05-19 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
US11667656B2 (en) 2021-01-27 2023-06-06 Apotex Inc. Crystalline forms of Tenofovir alafenamide
KR20220141457A (ko) 2021-04-13 2022-10-20 경동제약 주식회사 신규 결정형의 테노포비어 알라펜아미드 말레산염 및 이를 포함하는 약제학적 조성물
CA3238270A1 (en) 2021-12-03 2023-06-08 Gediminas J. Brizgys Therapeutic compounds for hiv virus infection
WO2023102239A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
US20230203071A1 (en) 2021-12-03 2023-06-29 Zhimin Du Therapeutic compounds for hiv virus infection
TW202400172A (zh) 2022-04-06 2024-01-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
TW202402280A (zh) 2022-07-01 2024-01-16 美商基利科學股份有限公司 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物
WO2024044477A1 (en) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302585A (en) * 1990-04-20 1994-04-12 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
DE10399025I2 (de) 1990-09-14 2007-11-08 Acad Of Science Czech Republic Wirkstoffvorläufer von Phosphonaten
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US5468768A (en) 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
WO1998004569A1 (en) 1996-07-26 1998-02-05 Gilead Sciences, Inc. Nucleotide analogs
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
ES2198003T3 (es) 1996-07-26 2004-01-16 Gilead Sciences, Inc. Analogos de nucleotidos.
ES2249511T3 (es) 1997-07-25 2006-04-01 Gilead Sciences, Inc. Composiciones de analogos de nucleotido y procedimiento de sintesis.
PL213214B1 (pl) 2000-07-21 2013-01-31 Gilead Sciences Diastereoizomerycznie wzbogacone proleki fosfonianowych analogów nukleotydowych oraz kompozycje zawierajace takie zwiazki
MY131488A (en) 2002-04-08 2007-08-30 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
JP2004288898A (ja) * 2003-03-24 2004-10-14 Canon Inc 太陽電池モジュールの製造方法
ECSP045074A (es) 2004-04-22 2004-05-28 Inhibidores hidroxipirimidinona carboxamida n-sustituida de integrasa de vih
JP4629104B2 (ja) 2004-05-21 2011-02-09 日本たばこ産業株式会社 ４−オキソキノリン誘導体および抗ｈｉｖ剤を含む併用剤
WO2007013086A1 (en) 2005-07-26 2007-02-01 Hetero Drugs Limited Novel polymorphs of tenofovir disoproxil fumarate
CA2653374A1 (en) 2006-07-07 2008-01-24 Manoj C. Desai Modulators of pharmacokinetic properties of therapeutics
EP2046792B1 (en) 2006-07-12 2015-02-25 Mylan Laboratories Limited Process for the preparation of tenofovir
LT2487161T (lt) 2007-02-23 2016-11-10 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
EP2160394A1 (en) 2007-05-22 2010-03-10 Ultimorphix Technologies B.v. Tenofovir disoproxil hemi-fumaric acid co-crystal
JP5722213B2 (ja) 2008-05-02 2015-05-20 ギリアード サイエンシーズ， インコーポレイテッド 医薬薬剤の加工性を改良するための固体担体粒子の使用
WO2010091197A2 (en) 2009-02-06 2010-08-12 Gilead Sciences, Inc. Tablets for combination therapy
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
TWI556840B (zh) 2010-11-19 2016-11-11 吉李德科學股份有限公司 治療用組成物
FI2744810T4 (fi) 2011-08-16 2023-11-22 Gilead Sciences Inc Tenofoviirialafenamidihemifumaraatti
WO2013052094A2 (en) 2011-10-07 2013-04-11 Gilead Sciences, Inc. Methods for preparing anti-viral nucleotide analogs
EP2809323A1 (en) † 2012-02-03 2014-12-10 Gilead Sciences, Inc. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections

Also Published As

Publication number Publication date
AU2012296622B2 (en) 2014-09-11
PL2744810T3 (pl) 2017-04-28
PT2744810T (pt) 2016-11-04
DK2744810T3 (en) 2016-12-05
HUE031253T2 (en) 2017-07-28
AP2014007437A0 (en) 2014-02-28
JP2015038149A (ja) 2015-02-26
WO2013025788A1 (en) 2013-02-21
US8754065B2 (en) 2014-06-17
ME02612B (me) 2017-06-20
CY1118385T1 (el) 2017-06-28
IL230949A0 (en) 2014-03-31
EP2744810B1 (en) 2016-10-05
FI2744810T4 (fi) 2023-11-22
MD4508B1 (ro) 2017-08-31
EP3831832A1 (en) 2021-06-09
MD20140011A2 (en) 2014-05-31
UY34262A (es) 2013-04-05
JP2014528924A (ja) 2014-10-30
KR20140054068A (ko) 2014-05-08
DK2744810T4 (da) 2023-11-20
RS55353B1 (sr) 2017-03-31
US9296769B2 (en) 2016-03-29
CR20140072A (es) 2014-06-19
BR112014003420B1 (pt) 2021-07-20
PE20141328A1 (es) 2014-10-04
CA2845553C (en) 2019-05-28
IL230949A (en) 2015-09-24
US20130065856A1 (en) 2013-03-14
ES2608871T5 (es) 2024-04-04
AP3639A (en) 2016-03-13
CA2845553A1 (en) 2013-02-21
JP5956537B2 (ja) 2016-07-27
JP5651275B2 (ja) 2015-01-07
HK1199026A1 (en) 2015-06-19
TW201321396A (zh) 2013-06-01
MX2014001549A (es) 2014-02-27
SI2744810T1 (sl) 2017-01-31
KR101612642B1 (ko) 2016-04-14
HRP20161696T4 (hr) 2023-10-13
MD4508C1 (ro) 2018-03-31
JP6280162B2 (ja) 2018-02-14
MA35350B1 (fr) 2014-08-01
JP2020040972A (ja) 2020-03-19
JP2016169228A (ja) 2016-09-23
RS55353B2 (sr) 2023-11-30
AR087546A1 (es) 2014-04-03
PL2744810T5 (pl) 2024-02-05
IL240649A0 (en) 2015-09-24
SI2744810T2 (sl) 2023-11-30
CN103732594A (zh) 2014-04-16
LT2744810T (lt) 2016-11-25
CO6880063A2 (es) 2014-02-28
JP2018065870A (ja) 2018-04-26
CN110343135A (zh) 2019-10-18
SG2014011548A (en) 2014-09-26
UA115311C2 (uk) 2017-10-25
EP3070088A1 (en) 2016-09-21
IN2014DN01012A (es) 2015-05-15
US20140187773A1 (en) 2014-07-03
EP2744810A1 (en) 2014-06-25
TWI516499B (zh) 2016-01-11
BR112014003420A2 (pt) 2017-03-01
NZ620421A (en) 2015-05-29
EP2744810B2 (en) 2023-09-13
ZA201400582B (en) 2017-11-29
AU2012296622C1 (en) 2017-02-16
CL2014000370A1 (es) 2014-09-05
MX336627B (es) 2016-01-26
ES2608871T3 (es) 2017-04-17
EA027768B1 (ru) 2017-08-31
HRP20161696T1 (hr) 2017-02-24
SMT201600476B (it) 2017-03-08
EA201490208A1 (ru) 2014-06-30
AU2012296622A1 (en) 2013-05-09

Similar Documents

Publication Publication Date Title
ECSP14013206A (es) Hemifumarato de tenofovir alafenamida
EA201491287A1 (ru) Комбинированная терапия, включающая тенофовир алафенамида гемифумарат и кобицистат, для применения для лечения вирусных инфекций
CY1120929T1 (el) Λιπιδια για συστασεις διανομης θεραπευτικου παραγοντα
CY1124469T1 (el) Παραγωγα πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων
HRP20181497T1 (hr) Derivati purina za liječenje virusnih infekcija
USD675331S1 (en) Ejaculation promotion apparatus
USD674907S1 (en) Ejaculation promotion apparatus
USD674909S1 (en) Ejaculation promotion apparatus
USD674908S1 (en) Ejaculation promotion apparatus
USD674906S1 (en) Ejaculation promotion apparatus
TWD163303S (zh) 手推輪椅之部分
AU2013328732A8 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
EP3010512A4 (en) PHOSPHONATE-SUBSTITUTED CYCLIC NUCLEOSIDE DERIVATIVES AND METHODS OF USE FOR THE TREATMENT OF VIRAL DISEASES
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
CR20140175A (es) Compuestos y métodos para mejorar las respuestas inmunitarias innatas
BR112013024809A2 (pt) tratamento para infecção com vírus de hepatite b sozinho ou em combinação com vírus de hepatite delta e doenças do fígado associadas
IN2013MU01967A (es)
BR112013032839A2 (pt) clínica de diálise com emissão zero
TH162157A (th) เทโนโฟเวียร์ อะลาเฟนามายด์ เฮมิฟูมาเรต(Tenofovir alafenamide hemifumarate)
TWD178255S (zh) 齒間刷
CA140705S (en) Modular wheelchair lap tray
TWD176246S (zh) 齒間刷
UA81083U (ru) Способ лечения больных острыми респираторными вирусными инфекциями
TH129939B (th) องค์ประกอบสำหรับรักษาตับอักเสบบีเรื้อรังซึ่งมีคลีวูดีน (clevudine) และแอดีโฟเวียร์ไดไพวอกซิล (adefovir dipivoxil)